WO2009063953A1 - フェニルピラゾール誘導体 - Google Patents

フェニルピラゾール誘導体 Download PDF

Info

Publication number
WO2009063953A1
WO2009063953A1 PCT/JP2008/070712 JP2008070712W WO2009063953A1 WO 2009063953 A1 WO2009063953 A1 WO 2009063953A1 JP 2008070712 W JP2008070712 W JP 2008070712W WO 2009063953 A1 WO2009063953 A1 WO 2009063953A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
disorder
halogeno
general formula
sleep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/070712
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
Toshio Nakamura
Makoto Tatsuzuki
Dai Nozawa
Tomoko Tamita
Seiji Masuda
Hiroshi Ohta
Shuhei Kashiwa
Aya Fujino
Shigeyuki Chaki
Toshiharu Shimazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12/741,754 priority Critical patent/US7888354B2/en
Priority to NZ585661A priority patent/NZ585661A/en
Priority to JP2009541174A priority patent/JP4543344B2/ja
Priority to HK10112206.3A priority patent/HK1145834B/xx
Priority to CN200880115707XA priority patent/CN101855211B/zh
Priority to DK08849725.0T priority patent/DK2221298T3/da
Priority to BRPI0820432A priority patent/BRPI0820432B8/pt
Priority to AU2008321823A priority patent/AU2008321823B2/en
Priority to CA2705502A priority patent/CA2705502C/en
Priority to SI200831096T priority patent/SI2221298T1/sl
Priority to HRP20131060AT priority patent/HRP20131060T1/hr
Priority to EP08849725.0A priority patent/EP2221298B1/en
Priority to MX2010005225A priority patent/MX2010005225A/es
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Priority to RU2010123924/04A priority patent/RU2480456C2/ru
Priority to PL08849725T priority patent/PL2221298T3/pl
Priority to RS20130586A priority patent/RS53125B/sr
Priority to PH1/2012/501917A priority patent/PH12012501917A1/en
Priority to ES08849725T priority patent/ES2436146T3/es
Publication of WO2009063953A1 publication Critical patent/WO2009063953A1/ja
Priority to IL205509A priority patent/IL205509A/en
Priority to ZA2010/03111A priority patent/ZA201003111B/en
Anticipated expiration legal-status Critical
Priority to US12/951,978 priority patent/US8193176B2/en
Priority to US12/951,964 priority patent/US8183387B2/en
Priority to IL236083A priority patent/IL236083A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/JP2008/070712 2007-11-13 2008-11-13 フェニルピラゾール誘導体 Ceased WO2009063953A1 (ja)

Priority Applications (23)

Application Number Priority Date Filing Date Title
MX2010005225A MX2010005225A (es) 2007-11-13 2008-11-13 Derivados de fenilpirazol.
JP2009541174A JP4543344B2 (ja) 2007-11-13 2008-11-13 フェニルピラゾール誘導体
HK10112206.3A HK1145834B (en) 2007-11-13 2008-11-13 Phenylpyrazole derivatives
CN200880115707XA CN101855211B (zh) 2007-11-13 2008-11-13 苯基吡唑衍生物
DK08849725.0T DK2221298T3 (da) 2007-11-13 2008-11-13 Phenylpyrazolderivater
BRPI0820432A BRPI0820432B8 (pt) 2007-11-13 2008-11-13 derivados de fenilpirazol apresentando atividade de antagonista de receptor de histamina h3 e um agente profilático ou terapeutico compreendendo tais derivados
AU2008321823A AU2008321823B2 (en) 2007-11-13 2008-11-13 Phenylpyrazole derivatives
CA2705502A CA2705502C (en) 2007-11-13 2008-11-13 Phenylpyrazole derivatives
NZ585661A NZ585661A (en) 2007-11-13 2008-11-13 Phenylpyrazole derivatives
HRP20131060AT HRP20131060T1 (hr) 2007-11-13 2008-11-13 Derivati fenilpirazola
RU2010123924/04A RU2480456C2 (ru) 2007-11-13 2008-11-13 Фенилпиразольные производные
US12/741,754 US7888354B2 (en) 2007-11-13 2008-11-13 Phenylpyrazole derivatives
SI200831096T SI2221298T1 (sl) 2007-11-13 2008-11-13 Derivati fenilpirazola
EP08849725.0A EP2221298B1 (en) 2007-11-13 2008-11-13 Phenylpyrazole derivatives
PL08849725T PL2221298T3 (pl) 2007-11-13 2008-11-13 Pochodne fenylopirazolu
RS20130586A RS53125B (sr) 2007-11-13 2008-11-13 Derivati fenilpirazola
PH1/2012/501917A PH12012501917A1 (en) 2007-11-13 2008-11-13 Phenylpyrazole derivatives
ES08849725T ES2436146T3 (es) 2007-11-13 2008-11-13 Derivados de fenilpirazol
IL205509A IL205509A (en) 2007-11-13 2010-05-03 Phenyl-pyrazole derivatives
ZA2010/03111A ZA201003111B (en) 2007-11-13 2010-05-04 Phenylpyrazole derivatives
US12/951,978 US8193176B2 (en) 2007-11-13 2010-11-22 Phenylpyrazole derivatives
US12/951,964 US8183387B2 (en) 2007-11-13 2010-11-22 Phenylpyrazole derivatives
IL236083A IL236083A (en) 2007-11-13 2014-12-04 Phenyl-pyrazole derivatives

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007294040 2007-11-13
JP2007-294040 2007-11-13
JP2008153736 2008-06-12
JP2008-153736 2008-06-12

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US12/741,754 A-371-Of-International US7888354B2 (en) 2007-11-13 2008-11-13 Phenylpyrazole derivatives
US12/951,978 Division US8193176B2 (en) 2007-11-13 2010-11-22 Phenylpyrazole derivatives
US12/951,964 Division US8183387B2 (en) 2007-11-13 2010-11-22 Phenylpyrazole derivatives

Publications (1)

Publication Number Publication Date
WO2009063953A1 true WO2009063953A1 (ja) 2009-05-22

Family

ID=40638800

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/070712 Ceased WO2009063953A1 (ja) 2007-11-13 2008-11-13 フェニルピラゾール誘導体

Country Status (24)

Country Link
US (3) US7888354B2 (enExample)
EP (1) EP2221298B1 (enExample)
JP (2) JP4543344B2 (enExample)
KR (1) KR101571176B1 (enExample)
CN (1) CN101855211B (enExample)
AU (1) AU2008321823B2 (enExample)
BR (1) BRPI0820432B8 (enExample)
CA (1) CA2705502C (enExample)
CY (1) CY1114877T1 (enExample)
DK (1) DK2221298T3 (enExample)
ES (1) ES2436146T3 (enExample)
HR (1) HRP20131060T1 (enExample)
IL (2) IL205509A (enExample)
MX (1) MX2010005225A (enExample)
MY (1) MY173546A (enExample)
NZ (1) NZ585661A (enExample)
PH (1) PH12012501917A1 (enExample)
PL (1) PL2221298T3 (enExample)
PT (1) PT2221298E (enExample)
RS (1) RS53125B (enExample)
RU (1) RU2480456C2 (enExample)
SI (1) SI2221298T1 (enExample)
WO (1) WO2009063953A1 (enExample)
ZA (1) ZA201003111B (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013085018A1 (ja) 2011-12-08 2013-06-13 大正製薬株式会社 フェニルピロール誘導体
WO2013100054A1 (ja) 2011-12-27 2013-07-04 大正製薬株式会社 フェニルトリアゾール誘導体
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
JP2016501246A (ja) * 2012-12-07 2016-01-18 ケモセントリックス，インコーポレイティド ジアゾールラクタム
JP2016506910A (ja) * 2013-01-17 2016-03-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ疾患の処置のためのオキシトシン受容体アゴニスト
US10568870B2 (en) 2016-04-07 2020-02-25 Chemocentryx, Inc. Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113776A1 (en) * 2006-12-14 2010-05-06 Taisho Pharmaceutical Co.,Ltd. Pyrazole derivative
PL2221298T3 (pl) * 2007-11-13 2014-05-30 Taisho Pharmaceutical Co Ltd Pochodne fenylopirazolu
JP5740838B2 (ja) * 2009-05-12 2015-07-01 大正製薬株式会社 フェニルピラゾール誘導体

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012190A2 (en) 2000-08-08 2002-02-14 Ortho Mcneil Pharmaceutical, Inc. Non-imidazole aryloxypiperidines as h3 receptor ligands
WO2002040461A2 (en) 2000-11-17 2002-05-23 Abbott Laboratories Aminoalkoxybiphenyl carboxamides as histamine-3 receptor ligands and their therapeutic applications
WO2005007644A1 (ja) 2003-06-27 2005-01-27 Banyu Pharmaceutical Co., Ltd ヘテロアリールオキシ含窒素飽和へテロ環誘導体
WO2005097778A1 (en) 2004-04-08 2005-10-20 Glaxo Group Limited Tetrahydrobenzazepines as histamine h3 receptor ligands
WO2005097751A2 (en) 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds as histamine h3-receptor ligands
WO2005118547A1 (fr) 2004-05-25 2005-12-15 Sanofi-Aventis Derives de tetrahydroisoquinolilsulfonamides, leur preparation et leur utilisation en therapeutique
WO2006014136A1 (en) 2004-08-02 2006-02-09 Astrazeneca Ab Piperidine derivatives as histamine h3 receptor ligands
WO2006023462A1 (en) 2004-08-23 2006-03-02 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
WO2006046131A1 (en) 2004-10-29 2006-05-04 Pfizer Products Inc. Tetralin histamine-3 receptor antagonists
WO2006045416A1 (en) 2004-10-19 2006-05-04 F. Hoffmann-La Roche Ag Quinoline derivatives
WO2006059778A1 (ja) 2004-12-01 2006-06-08 Banyu Pharmaceutical Co., Ltd. 置換ピリドン誘導体
WO2006061193A1 (en) 2004-12-07 2006-06-15 Glaxo Group Limited Indenyl derivatives and use thereof for the treatment of neurological disorders
WO2006103057A1 (en) 2005-03-31 2006-10-05 Ucb Pharma, S.A. Compounds comprising an oxazoline or thiazoline moiety, processes for making them, and their uses
WO2006107661A1 (en) 2005-04-01 2006-10-12 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
WO2007009741A1 (en) * 2005-07-19 2007-01-25 Glaxo Group Limited Piperazinone derivatives useful as histamine h3 receptor antagonists and/or inverse agonists
WO2007009739A1 (en) * 2005-07-19 2007-01-25 Glaxo Group Limited Compounds
WO2007094962A2 (en) 2006-02-09 2007-08-23 Athersys, Inc. Pyrazoles for the treatment of obesity and other cns disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
CA2440238C (en) * 2001-03-16 2011-09-13 Abbott Laboratories Novel amines as histamine-3 receptor ligands and their therapeutic applications
DE102005033448A1 (de) * 2005-07-18 2007-01-25 Josef Gail Druckgas-Zylinderläufermotor
US20100113776A1 (en) 2006-12-14 2010-05-06 Taisho Pharmaceutical Co.,Ltd. Pyrazole derivative
CN101711232A (zh) * 2007-04-12 2010-05-19 Dsm精细化学奥地利Nfg两合公司 邻-氯甲基苯基乙醛酸酯、(e)-2-(2-氯甲基苯基)-2-烷氧亚胺基乙酸酯的改进制备方法以及用于这些制备方法的新型中间体
PL2221298T3 (pl) * 2007-11-13 2014-05-30 Taisho Pharmaceutical Co Ltd Pochodne fenylopirazolu

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012190A2 (en) 2000-08-08 2002-02-14 Ortho Mcneil Pharmaceutical, Inc. Non-imidazole aryloxypiperidines as h3 receptor ligands
WO2002040461A2 (en) 2000-11-17 2002-05-23 Abbott Laboratories Aminoalkoxybiphenyl carboxamides as histamine-3 receptor ligands and their therapeutic applications
WO2005007644A1 (ja) 2003-06-27 2005-01-27 Banyu Pharmaceutical Co., Ltd ヘテロアリールオキシ含窒素飽和へテロ環誘導体
WO2005097751A2 (en) 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds as histamine h3-receptor ligands
WO2005097778A1 (en) 2004-04-08 2005-10-20 Glaxo Group Limited Tetrahydrobenzazepines as histamine h3 receptor ligands
WO2005118547A1 (fr) 2004-05-25 2005-12-15 Sanofi-Aventis Derives de tetrahydroisoquinolilsulfonamides, leur preparation et leur utilisation en therapeutique
WO2006014136A1 (en) 2004-08-02 2006-02-09 Astrazeneca Ab Piperidine derivatives as histamine h3 receptor ligands
WO2006023462A1 (en) 2004-08-23 2006-03-02 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
WO2006045416A1 (en) 2004-10-19 2006-05-04 F. Hoffmann-La Roche Ag Quinoline derivatives
WO2006046131A1 (en) 2004-10-29 2006-05-04 Pfizer Products Inc. Tetralin histamine-3 receptor antagonists
WO2006059778A1 (ja) 2004-12-01 2006-06-08 Banyu Pharmaceutical Co., Ltd. 置換ピリドン誘導体
WO2006061193A1 (en) 2004-12-07 2006-06-15 Glaxo Group Limited Indenyl derivatives and use thereof for the treatment of neurological disorders
WO2006103057A1 (en) 2005-03-31 2006-10-05 Ucb Pharma, S.A. Compounds comprising an oxazoline or thiazoline moiety, processes for making them, and their uses
WO2006107661A1 (en) 2005-04-01 2006-10-12 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
WO2007009741A1 (en) * 2005-07-19 2007-01-25 Glaxo Group Limited Piperazinone derivatives useful as histamine h3 receptor antagonists and/or inverse agonists
WO2007009739A1 (en) * 2005-07-19 2007-01-25 Glaxo Group Limited Compounds
WO2007094962A2 (en) 2006-02-09 2007-08-23 Athersys, Inc. Pyrazoles for the treatment of obesity and other cns disorders

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
ARRANG J-M. ET AL., NATURE, vol. 302, 1983, pages 832 - 837
BABIER A.J. ET AL., BR. J. PHARMACOL., vol. 143, 2004, pages 649 - 661
BROWN R.E. ET AL., PROGRESS IN NEUROBIOLOGY, vol. 63, 2001, pages 637 - 672
FOX G.B. ET AL., J. PHARMACOL. EXP. THER., vol. 313, 2005, pages 176 - 190
HANCOCK A.A. ET AL., CURR. OPIN. INVESTIG. DRUG, vol. 4, pages 1190 - 1197
HUANG Y-W. ET AL., BEHAVIOURAL BRAIN RESEARCH, vol. 151, 2004, pages 287 - 293
HUANG Z-L. ET AL., PROG. NATR. ACAD. SCI., vol. 103, 2006, pages 4687 - 4692
J. PHARMACOL. EXP. THER., vol. 301, no. 1, April 2002 (2002-04-01), pages 249 - 257
JOURNAL OF AMERICAN CHEMICAL SOCIETY, vol. 77, 1955, pages 633
JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, 2002, pages 3972 - 3983
KOMATER V.A. ET AL., BEHAVIOURAL BRAIN RESEARCH, vol. 159, 2005, pages 295 - 300
KUNZ ET AL., SYNLETT, vol. 15, 2003, pages 2428 - 2439
LEURS R. ET AL., DRUG DISCOVERY TODAY, vol. 10, 2005, pages 1613 - 1627
LEURS R. ET AL., NATURE DRUG DISCOVERY, vol. 4, 2005, pages 107 - 122
LOVENBERG T.W. ET AL., MOLECULAR PHARMACOLOGY, vol. 55, 1999, pages 1101 - 1107
MCLEOD R.L. ET AL., AM. J. RHINO!., vol. 13, 1999, pages 391 - 399
NEUROPSYCHOPHARMACOLOGY, vol. 32, no. 3, March 2007 (2007-03-01), pages 514 - 521
PASSANI M.B. ET AL., NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, vol. 24, 2000, pages 107 - 113
PASSANI M.B. ET AL., TRENDS IN PHARMACOL. SCI., vol. 25, 2004, pages 618 - 625
SCHWARTZ J.C. ET AL., TRENDS IN PHARMACOL. SCI., vol. 7, 1986, pages 24 - 28
See also references of EP2221298A4
SHIMAZAKI ET AL., EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 575, 2007, pages 94 - 97

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2013085018A1 (ja) * 2011-12-08 2015-04-27 大正製薬株式会社 フェニルピロール誘導体
WO2013085018A1 (ja) 2011-12-08 2013-06-13 大正製薬株式会社 フェニルピロール誘導体
US9284324B2 (en) 2011-12-08 2016-03-15 Taisho Pharmaceutical Co., Ltd Phenylpyrrole derivative
AU2012349290B2 (en) * 2011-12-08 2017-03-23 Taisho Pharmaceutical Co., Ltd. Phenylpyrrole derivative
WO2013100054A1 (ja) 2011-12-27 2013-07-04 大正製薬株式会社 フェニルトリアゾール誘導体
JPWO2013100054A1 (ja) * 2011-12-27 2015-05-11 大正製薬株式会社 フェニルトリアゾール誘導体
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
US10744118B2 (en) 2012-12-07 2020-08-18 Chemocentryx, Inc. Diazole lactams
JP2016501246A (ja) * 2012-12-07 2016-01-18 ケモセントリックス，インコーポレイティド ジアゾールラクタム
US11759454B2 (en) 2012-12-07 2023-09-19 Chemocentryx, Inc. Diazole lactams
JP2016506910A (ja) * 2013-01-17 2016-03-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ疾患の処置のためのオキシトシン受容体アゴニスト
US11744822B2 (en) 2016-04-07 2023-09-05 Chemocentryx, Inc. Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors
US10568870B2 (en) 2016-04-07 2020-02-25 Chemocentryx, Inc. Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors

Also Published As

Publication number Publication date
IL236083A (en) 2016-12-29
KR101571176B1 (ko) 2015-11-23
BRPI0820432B1 (pt) 2020-01-14
BRPI0820432B8 (pt) 2021-05-25
SI2221298T1 (sl) 2013-12-31
US8193176B2 (en) 2012-06-05
JPWO2009063953A1 (ja) 2011-03-31
MX2010005225A (es) 2010-05-27
JP5375639B2 (ja) 2013-12-25
JP2010143943A (ja) 2010-07-01
CA2705502C (en) 2016-01-26
US20100267687A1 (en) 2010-10-21
CA2705502A1 (en) 2009-05-22
PL2221298T3 (pl) 2014-05-30
AU2008321823B2 (en) 2013-03-07
HK1145834A1 (en) 2011-05-06
KR20100083795A (ko) 2010-07-22
US7888354B2 (en) 2011-02-15
EP2221298B1 (en) 2013-11-06
PT2221298E (pt) 2013-12-03
ZA201003111B (en) 2011-08-31
RU2010123924A (ru) 2011-12-20
HRP20131060T1 (hr) 2013-12-20
DK2221298T3 (da) 2013-11-18
CN101855211A (zh) 2010-10-06
MY173546A (en) 2020-02-04
EP2221298A1 (en) 2010-08-25
US20110065667A1 (en) 2011-03-17
RS53125B (sr) 2014-06-30
ES2436146T3 (es) 2013-12-27
PH12012501917A1 (en) 2014-10-17
BRPI0820432A2 (pt) 2015-05-26
US8183387B2 (en) 2012-05-22
EP2221298A4 (en) 2011-09-21
IL205509A (en) 2015-09-24
CN101855211B (zh) 2013-06-12
RU2480456C2 (ru) 2013-04-27
NZ585661A (en) 2012-04-27
US20110065668A1 (en) 2011-03-17
IL236083A0 (en) 2015-01-29
IL205509A0 (en) 2010-12-30
AU2008321823A1 (en) 2009-05-22
CY1114877T1 (el) 2016-12-14
JP4543344B2 (ja) 2010-09-15

Similar Documents

Publication Publication Date Title
WO2009063953A1 (ja) フェニルピラゾール誘導体
NZ617334A (en) Cyclopropyl amine derivatives
EP1845081A4 (en) amide
MX2011008336A (es) Derivados de dihidroquinolinona.
WO2007085556A3 (en) Use of 4-imidazole derivatives for cns disorders
NO343929B3 (no) 1-[2-(2,4-dimetylfenylsulfanyl-fenyl]-piperazin som en forbindelse med kombinert serotoninreopptak, 5-HT3- og 5HT1A-aktivitet for behandlingen av kognitiv smerte
NO20085067L (no) 4,5-difenyl-pyrimidinyl substituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
NO20085064L (no) 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
ATE478058T3 (de) 3,7-diamino-10h-phenothiazinsalze und ihre verwendung
BR112012027640A2 (pt) composto, composição farmacêutica uso de um composto, e, métodos de preparar uma composição farmacêutica, de inibir a função da 11beta-hidroxiesteroide desidrogenase do tipo 1 e de tratamento ou prevenção de um distúrbio
NO20084403L (no) Cykloheksylpyrazol-lactamderivater som inhibitorer av II-beta-hydroksysteroid dehydrogenase I
NZ705710A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
MX2011011489A (es) Derivados de isoxazol-piridina.
NO20083369L (no) Anvendelse av substituert 2-imidazol av imidazolinderivater
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
NO20082112L (no) 3-Amino-2-arylpropylazaindoler og deres anvendelse
MX2011011273A (es) Derivados de isoxazol-pirazol.
CA2702933A1 (en) Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof
WO2007057790A3 (en) Substituted bicyclic pyrimidone derivatives
BR112014004275A2 (pt) derivados de isoxazolina como compostos inseticidas
PH12014501293A1 (en) Phenylpyrrole derivative
NZ620048A (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
BRPI0811220A2 (pt) Compostos terapêuticos
NO20082589L (no) Nye indolizinderivater, fremgangsmate for fremstilling av samme og terapeutiske sammensetninger som inbefatter samme

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880115707.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08849725

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009541174

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107009179

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 205509

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12741754

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 3280/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12010501039

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2705502

Country of ref document: CA

Ref document number: MX/A/2010/005225

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008321823

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 585661

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2008321823

Country of ref document: AU

Date of ref document: 20081113

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008849725

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010123924

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: PI 2010002187

Country of ref document: MY

WWE Wipo information: entry into national phase

Ref document number: P-2013/0586

Country of ref document: RS

ENP Entry into the national phase

Ref document number: PI0820432

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100513